Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models.
Using transgenic mice expressing human cystatin C (encoded by CST3), we show that cystatin C binds soluble amyloid-beta peptide and inhibits cerebral amyloid deposition in amyloid-beta precursor protein (APP) transgenic mice. Cystatin C expression twice that of the endogenous mouse cystatin C was sufficient to substantially diminish amyloid-beta deposition. Thus, cystatin C has a protective role in Alzheimer's disease pathogenesis, and modulation of cystatin C concentrations may have therapeutic implications for the disease.
Mi
Weiqian
W
Nathan S. Kline Institute, Orangeburg, New York 10962, USA.
Pawlik
Monika
M
Sastre
Magdalena
M
Jung
Sonia S
SS
Radvinsky
David S
DS
Klein
Andrew M
AM
Sommer
John
J
Schmidt
Stephen D
SD
Nixon
Ralph A
RA
Mathews
Paul M
PM
Levy
Efrat
E
D000544:Alzheimer Disease / Q000235:genetics / Q000378:metabolism*; D019943:Amino Acid Substitution; D016564:Amyloid beta-Protein Precursor / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D055316:Cystatin C; D015891:Cystatins / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D017354:Point Mutation
D016564:Amyloid beta-Protein Precursor; C525030:CST3 protein, human; C525031:Cst3 protein, mouse; D055316:Cystatin C; D015891:Cystatins